Keywords: Elan, Biogen Idec, Tysabri, FDA warnings, PML, Risk factors
Elan shares decline 5.8% on new US FDA call for stronger warning on Tysabri
Article | 8 February 2010
Irish drugmaker Elan saw its share price drop 5.8% to 5.05 euros, after it was revealed that the US Food and Drug Administration had found that the risk of a potentially fatal brain disorder with the firm’s multiple sclerosis drug Tysabri (natalizumab) increases as patients receive more infusions and called for stronger warnings. The agency did, however, reiterate its views that the benefits for MS patients associated with the drug still outweigh the risks.
The prescribing information for Tysabri, co-marketed with US biotechnology company Biogen Idec - originator of the drug - will be updated to warn about the higher risk of use of the drug over time. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
